Found 1131 Enz. Inhib. hit(s) with Target = 'Voltage-dependent N-type calcium channel subunit alpha-1B'
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataKi: 100nMAssay Description:Cells and methods: Functional inhibition of the sodium currents is studied using whole cell patch clamp methods (Hamill O. P., Marty A., Neher E., Sa...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataKi: 100nMAssay Description:Cells and methods: Functional inhibition of the sodium currents is studied using whole cell patch clamp methods (Hamill O. P., Marty A., Neher E., Sa...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataKi: 100nMAssay Description:Cells and methods: Functional inhibition of the sodium currents is studied using whole cell patch clamp methods (Hamill O. P., Marty A., Neher E., Sa...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataKi: 200nMAssay Description:Cells and methods: Functional inhibition of the sodium currents is studied using whole cell patch clamp methods (Hamill O. P., Marty A., Neher E., Sa...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataKi: 200nMAssay Description:Cells and methods: Functional inhibition of the sodium currents is studied using whole cell patch clamp methods (Hamill O. P., Marty A., Neher E., Sa...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataKi: 300nMAssay Description:Cells and methods: Functional inhibition of the sodium currents is studied using whole cell patch clamp methods (Hamill O. P., Marty A., Neher E., Sa...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataKi: 500nMAssay Description:Cells and methods: Functional inhibition of the sodium currents is studied using whole cell patch clamp methods (Hamill O. P., Marty A., Neher E., Sa...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataKi: 700nMAssay Description:Cells and methods: Functional inhibition of the sodium currents is studied using whole cell patch clamp methods (Hamill O. P., Marty A., Neher E., Sa...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Rattus norvegicus (Rat))
Eli Lilly
Curated by PDSP Ki Database
Eli Lilly
Curated by PDSP Ki Database
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Rattus norvegicus (Rat))
Eli Lilly
Curated by PDSP Ki Database
Eli Lilly
Curated by PDSP Ki Database
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Rattus norvegicus (Rat))
Eli Lilly
Curated by PDSP Ki Database
Eli Lilly
Curated by PDSP Ki Database
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataKi: 1.10E+3nMAssay Description:Cells and methods: Functional inhibition of the sodium currents is studied using whole cell patch clamp methods (Hamill O. P., Marty A., Neher E., Sa...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataKi: 1.70E+3nMAssay Description:Cells and methods: Functional inhibition of the sodium currents is studied using whole cell patch clamp methods (Hamill O. P., Marty A., Neher E., Sa...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataKi: 5.24E+3nMAssay Description:Binding affinity to verapamil site of N type calcium channelMore data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Rattus norvegicus (Rat))
Eli Lilly
Curated by PDSP Ki Database
Eli Lilly
Curated by PDSP Ki Database
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Rattus norvegicus (Rat))
Eli Lilly
Curated by PDSP Ki Database
Eli Lilly
Curated by PDSP Ki Database
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Rattus norvegicus (Rat))
Eli Lilly
Curated by PDSP Ki Database
Eli Lilly
Curated by PDSP Ki Database
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 1nMAssay Description:Inhibition of Cav2.2 (unknown origin) expressed in HEK293 cells assessed as decrease in KCl depolarization-induced Ca2+ influx measured for 5 mins by...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 1nMAssay Description:Inhibition of Cav2.2 (unknown origin) expressed in HEK293 cells assessed as decrease in KCl depolarization-induced Ca2+ influx measured for 5 mins by...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 1nMAssay Description:Inhibition of Cav2.2 (unknown origin) expressed in HEK293 cells assessed as decrease in KCl depolarization-induced Ca2+ influx measured for 5 mins by...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 2nMAssay Description:Inhibition of Cav2.2 (unknown origin) expressed in HEK293 cells assessed as decrease in KCl depolarization-induced Ca2+ influx measured for 5 mins by...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 2nMAssay Description:Inhibition of Cav2.2 (unknown origin) expressed in HEK293 cells assessed as decrease in KCl depolarization-induced Ca2+ influx measured for 5 mins by...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 2nMAssay Description:Inhibition of Cav2.2 (unknown origin) expressed in HEK293 cells assessed as decrease in KCl depolarization-induced Ca2+ influx measured for 5 mins by...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 3nMAssay Description:Inhibition of Cav2.2 (unknown origin) expressed in HEK293 cells assessed as decrease in KCl depolarization-induced Ca2+ influx measured for 5 mins by...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 3nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 3nMAssay Description:Inhibition of Cav2.2 (unknown origin) expressed in HEK293 cells assessed as decrease in KCl depolarization-induced Ca2+ influx measured for 5 mins by...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 4nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 5nMAssay Description:Inhibition of Cav2.2 (unknown origin) expressed in HEK293 cells assessed as decrease in KCl depolarization-induced Ca2+ influx measured for 5 mins by...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 6nMAssay Description:Inhibition of Cav2.2 (unknown origin) expressed in HEK293 cells assessed as decrease in KCl depolarization-induced Ca2+ influx measured for 5 mins by...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 6nMAssay Description:Inhibition of Cav2.2 (unknown origin) expressed in HEK293 cells assessed as decrease in KCl depolarization-induced Ca2+ influx measured for 5 mins by...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 7nMAssay Description:Inhibition of Cav2.2 (unknown origin) expressed in HEK293 cells assessed as decrease in KCl depolarization-induced Ca2+ influx measured for 5 mins by...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 7nMAssay Description:Inhibition of Cav2.2 (unknown origin) expressed in HEK293 cells assessed as decrease in KCl depolarization-induced Ca2+ influx measured for 5 mins by...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 9nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 11nMAssay Description:Inhibition of Cav2.2 (unknown origin) expressed in HEK293 cells assessed as decrease in KCl depolarization-induced Ca2+ influx measured for 5 mins by...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 12nMAssay Description:Inhibition of Cav2.2 (unknown origin) expressed in HEK293 cells assessed as decrease in KCl depolarization-induced Ca2+ influx measured for 5 mins by...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 12nMAssay Description:Inhibition of high frequency stimulation-induced Cav2.2 (unknown origin) expressed in HEK293 cells at -80 mV holding membrane potential by automated ...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 16nMAssay Description:Inhibition of high frequency stimulation-induced Cav2.2 (unknown origin) expressed in HEK293 cells at -80 mV holding membrane potential by automated ...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 20nMAssay Description:Inhibition of Cav2.2 expressed HEK293 cells assessed as inhibition of calcium flux by FLIPR assay in presence of 4 mM of potassiumMore data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 20nMAssay Description:Inhibition of Cav2.2 (unknown origin) expressed in HEK293 cells assessed as decrease in KCl depolarization-induced Ca2+ influx measured for 5 mins by...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 22nMAssay Description:Inhibition of Cav2.2 (unknown origin) expressed in HEK293 cells assessed as decrease in KCl depolarization-induced Ca2+ influx measured for 5 mins by...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 24nMAssay Description:Inhibition of low frequency stimulation-induced Cav2.2 (unknown origin) expressed in HEK293 cells at -80 mV holding membrane potential by automated p...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 25nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 28nMAssay Description:Inhibition of high frequency stimulation-induced Cav2.2 (unknown origin) expressed in HEK293 cells at -80 mV holding membrane potential by automated ...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 29nMAssay Description:Inhibition of high frequency stimulation-induced Cav2.2 (unknown origin) expressed in HEK293 cells at -80 mV holding membrane potential by automated ...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: 30nMAssay Description:Inhibition of Cav2.2 (unknown origin) expressed in HEK293 cells assessed as decrease in KCl depolarization-induced Ca2+ influx measured for 5 mins by...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Newron Pharmaceuticals
US Patent
Newron Pharmaceuticals
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair